FEASIBILITY - PHASE I DEVELOPMENT OF A NEXT GENERATION (REDUCED PROCESSING TIME) PATHOGEN REDUCTION AND BLOOD SAFETY SYSTEM

$3,225,374FY2017Department of the ArmyDOD

Terumo Bct Biotechnologies, Llc

Investigators